Korea, U.S. agrees to shorten reimburse notice by 20 days

Published: 2013-01-18 07:00:00

Updated: 2013-01-18 07:00:00

The governments of Korea and the U.S. agreed that the reimbursement notice of pharmaceutical products and medical devices should be shorted by 20 days from this January, according to the Korea Drug Research Association (KDRA).

The KDRA said that the nation’s innovative drug firms repeatedly as...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK